• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

过氧化物酶体增殖物激活受体α(PPARα)功能丧失会促进脂质稳态的表观遗传失调,从而在代谢功能障碍相关脂肪性肝病(MASLD)中引发铁死亡和焦亡脂毒性。

Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD).

作者信息

Theys Claudia, Vanderhaeghen Tineke, Van Dijck Evelien, Peleman Cedric, Scheepers Anne, Ibrahim Joe, Mateiu Ligia, Timmermans Steven, Vanden Berghe Tom, Francque Sven M, Van Hul Wim, Libert Claude, Vanden Berghe Wim

机构信息

Protein Chemistry, Proteomics and Epigenetic Signaling (PPES), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Center for Inflammation Research, VIB, Ghent, Belgium.

出版信息

Front Mol Med. 2024 Jan 8;3:1283170. doi: 10.3389/fmmed.2023.1283170. eCollection 2023.

DOI:10.3389/fmmed.2023.1283170
PMID:39086681
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11285560/
Abstract

Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) is a growing epidemic with an estimated prevalence of 20%-30% in Europe and the most common cause of chronic liver disease worldwide. The onset and progression of MASLD are orchestrated by an interplay of the metabolic environment with genetic and epigenetic factors. Emerging evidence suggests altered DNA methylation pattern as a major determinant of MASLD pathogenesis coinciding with progressive DNA hypermethylation and gene silencing of the liver-specific nuclear receptor PPARα, a key regulator of lipid metabolism. To investigate how PPARα loss of function contributes to epigenetic dysregulation in MASLD pathology, we studied DNA methylation changes in liver biopsies of WT and hepatocyte-specific PPARα KO mice, following a 6-week CDAHFD (choline-deficient, L-amino acid-defined, high-fat diet) or chow diet. Interestingly, genetic loss of PPARα function in hepatocyte-specific KO mice could be phenocopied by a 6-week CDAHFD diet in WT mice which promotes epigenetic silencing of PPARα function via DNA hypermethylation, similar to MASLD pathology. Remarkably, genetic and lipid diet-induced loss of PPARα function triggers compensatory activation of multiple lipid sensing transcription factors and epigenetic writer-eraser-reader proteins, which promotes the epigenetic transition from lipid metabolic stress towards ferroptosis and pyroptosis lipid hepatoxicity pathways associated with advanced MASLD. In conclusion, we show that PPARα function is essential to support lipid homeostasis and to suppress the epigenetic progression of ferroptosis-pyroptosis lipid damage associated pathways towards MASLD fibrosis.

摘要

代谢功能障碍相关脂肪性肝病(MASLD)是一种日益流行的疾病,在欧洲估计患病率为20%-30%,是全球慢性肝病最常见的病因。MASLD的发病和进展是由代谢环境与遗传和表观遗传因素相互作用所调控的。新出现的证据表明,DNA甲基化模式改变是MASLD发病机制的主要决定因素,这与肝脏特异性核受体PPARα(脂质代谢的关键调节因子)的渐进性DNA高甲基化和基因沉默相一致。为了研究PPARα功能丧失如何导致MASLD病理中的表观遗传失调,我们研究了野生型(WT)和肝细胞特异性PPARα基因敲除(KO)小鼠在接受6周胆碱缺乏、L-氨基酸定义的高脂肪饮食(CDAHFD)或普通饮食后肝脏活检中的DNA甲基化变化。有趣的是,WT小鼠接受6周CDAHFD饮食可模拟肝细胞特异性KO小鼠中PPARα功能的基因缺失,该饮食通过DNA高甲基化促进PPARα功能的表观遗传沉默,类似于MASLD病理。值得注意的是,遗传和脂质饮食诱导的PPARα功能丧失会触发多种脂质感应转录因子以及表观遗传书写-擦除-读取蛋白的代偿性激活,从而促进从脂质代谢应激向与晚期MASLD相关的铁死亡和焦亡脂质肝毒性途径的表观遗传转变。总之,我们表明PPARα功能对于维持脂质稳态以及抑制与MASLD纤维化相关的铁死亡-焦亡脂质损伤相关途径的表观遗传进展至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/010cc8c952ca/fmmed-03-1283170-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/01b886fd7454/fmmed-03-1283170-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/ae604fa5b131/fmmed-03-1283170-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/3e98c915dc7e/fmmed-03-1283170-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/cb5381b45a9e/fmmed-03-1283170-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/badba9eac858/fmmed-03-1283170-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/717d4e11236c/fmmed-03-1283170-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/d771f9c9c83d/fmmed-03-1283170-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/f31eb1e6dc0c/fmmed-03-1283170-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/010cc8c952ca/fmmed-03-1283170-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/01b886fd7454/fmmed-03-1283170-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/ae604fa5b131/fmmed-03-1283170-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/3e98c915dc7e/fmmed-03-1283170-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/cb5381b45a9e/fmmed-03-1283170-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/badba9eac858/fmmed-03-1283170-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/717d4e11236c/fmmed-03-1283170-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/d771f9c9c83d/fmmed-03-1283170-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/f31eb1e6dc0c/fmmed-03-1283170-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/abe4/11285560/010cc8c952ca/fmmed-03-1283170-g009.jpg

相似文献

1
Loss of PPARα function promotes epigenetic dysregulation of lipid homeostasis driving ferroptosis and pyroptosis lipotoxicity in metabolic dysfunction associated Steatotic liver disease (MASLD).过氧化物酶体增殖物激活受体α(PPARα)功能丧失会促进脂质稳态的表观遗传失调,从而在代谢功能障碍相关脂肪性肝病(MASLD)中引发铁死亡和焦亡脂毒性。
Front Mol Med. 2024 Jan 8;3:1283170. doi: 10.3389/fmmed.2023.1283170. eCollection 2023.
2
Hepatocyte-specific Epidermal Growth Factor Receptor Deletion Promotes Fibrosis but has no Effect on Steatosis in Fast-food Diet Model of Metabolic Dysfunction-associated Steatotic Liver Disease.肝细胞特异性表皮生长因子受体缺失促进肝纤维化,但对代谢相关脂肪性肝病的快餐饮食模型中的脂肪变性没有影响。
Cell Mol Gastroenterol Hepatol. 2024;18(4):101380. doi: 10.1016/j.jcmgh.2024.101380. Epub 2024 Jul 20.
3
Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.代谢相关脂肪性肝病中自噬、铁死亡、细胞凋亡和细胞焦亡
Front Biosci (Landmark Ed). 2024 Jan 19;29(1):30. doi: 10.31083/j.fbl2901030.
4
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease.铁死亡是代谢功能障碍相关脂肪性肝病中可靶向的有害因素。
Cell Death Differ. 2024 Sep;31(9):1113-1126. doi: 10.1038/s41418-024-01348-9. Epub 2024 Jul 26.
5
Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.髓系细胞表面表达的触发受体 2 通过调节巨噬细胞焦亡和炎症消退改善代谢相关脂肪性肝病的进展。
Metabolism. 2024 Jun;155:155911. doi: 10.1016/j.metabol.2024.155911. Epub 2024 Apr 10.
6
The ubiquitin-like modifier FAT10 is induced in MASLD and impairs the lipid-regulatory activity of PPARα.类泛素修饰因子FAT10在代谢相关脂肪性肝病(MASLD)中被诱导表达,并损害过氧化物酶体增殖物激活受体α(PPARα)的脂质调节活性。
Metabolism. 2024 Feb;151:155720. doi: 10.1016/j.metabol.2023.155720. Epub 2023 Nov 3.
7
Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.遗传敲除 STE20 型激酶 MST4 不能减轻小鼠饮食诱导的 MASLD 易感性。
Int J Mol Sci. 2024 Feb 19;25(4):2446. doi: 10.3390/ijms25042446.
8
Inhibition of ATGL alleviates MASH via impaired PPARα signalling that favours hydrophilic bile acid composition in mice.抑制脂肪甘油三酯脂肪酶(ATGL)可通过损害过氧化物酶体增殖物激活受体α(PPARα)信号通路来减轻小鼠的巨噬细胞活化综合征(MASH),该信号通路有利于亲水性胆汁酸组成。
J Hepatol. 2025 Apr;82(4):658-675. doi: 10.1016/j.jhep.2024.09.037. Epub 2024 Sep 30.
9
DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease.DNA 甲基化组分析揭示了晚期代谢功能相关脂肪性肝疾病中补体基因的表观遗传改变。
Clin Mol Hepatol. 2024 Oct;30(4):824-844. doi: 10.3350/cmh.2024.0229. Epub 2024 Jul 25.
10
Ileitis promotes MASLD progression via bile acid modulation and enhanced TGR5 signaling in ileal CD8 T cells.回肠炎通过胆汁酸调节和增强回肠 CD8 T 细胞中的 TGR5 信号促进 MASLD 进展。
J Hepatol. 2024 May;80(5):764-777. doi: 10.1016/j.jhep.2023.12.024. Epub 2024 Jan 4.

引用本文的文献

1
Gradual DNA methylation changes reveal transcription factors implicated in metabolic dysfunction-associated steatotic liver disease progression and epigenetic age acceleration.逐渐发生的DNA甲基化变化揭示了与代谢功能障碍相关的脂肪性肝病进展和表观遗传年龄加速有关的转录因子。
Clin Epigenetics. 2025 Aug 4;17(1):138. doi: 10.1186/s13148-025-01945-6.
2
Metabolic-Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies.代谢功能障碍相关脂肪性肝病:分子机制、临床意义及新兴治疗策略
Int J Mol Sci. 2025 Mar 25;26(7):2959. doi: 10.3390/ijms26072959.

本文引用的文献

1
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家组关于新的脂肪肝疾病命名的德尔菲共识声明。
J Hepatol. 2023 Dec;79(6):1542-1556. doi: 10.1016/j.jhep.2023.06.003. Epub 2023 Jun 24.
2
CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis.CDKN2A 缺失重塑脂代谢以使胶质母细胞瘤对铁死亡敏感。
Cancer Cell. 2023 Jun 12;41(6):1048-1060.e9. doi: 10.1016/j.ccell.2023.05.001. Epub 2023 May 25.
3
A Lipid Perspective on Regulated Pyroptosis.调控细胞焦亡的脂质视角
Int J Biol Sci. 2023 Apr 25;19(8):2333-2348. doi: 10.7150/ijbs.81017. eCollection 2023.
4
Tcf21 Alleviates Pancreatic Fibrosis by Regulating the Epithelial-Mesenchymal Transformation of Pancreatic Stellate Cells.Tcf21 通过调节胰腺星状细胞的上皮-间充质转化缓解胰腺纤维化。
Dig Dis Sci. 2023 Jul;68(7):3032-3042. doi: 10.1007/s10620-023-07849-w. Epub 2023 Mar 21.
5
Sirtuin 6-A Key Regulator of Hepatic Lipid Metabolism and Liver Health.Sirtuin 6-A 是肝脏脂质代谢和肝脏健康的关键调节因子。
Cells. 2023 Feb 19;12(4):663. doi: 10.3390/cells12040663.
6
Programmed cell death and lipid metabolism of macrophages in NAFLD.非酒精性脂肪性肝病中巨噬细胞的程序性细胞死亡和脂质代谢。
Front Immunol. 2023 Jan 18;14:1118449. doi: 10.3389/fimmu.2023.1118449. eCollection 2023.
7
Differential DNA methylation of steatosis and non-alcoholic fatty liver disease in adolescence.青少年非酒精性脂肪性肝病与脂肪变性的 DNA 甲基化差异。
Hepatol Int. 2023 Jun;17(3):584-594. doi: 10.1007/s12072-022-10469-7. Epub 2023 Feb 3.
8
High-fat diet induced obesity alters Dnmt1 and Dnmt3a levels and global DNA methylation in mouse ovary and testis.高脂饮食诱导的肥胖改变了小鼠卵巢和睾丸中Dnmt1和Dnmt3a的水平以及整体DNA甲基化。
Histochem Cell Biol. 2023 Apr;159(4):339-352. doi: 10.1007/s00418-022-02173-2. Epub 2023 Jan 9.
9
PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?PPARα在非酒精性脂肪性肝病的表观遗传驱动位置:表观遗传药物的新治疗机会?
Biomedicines. 2022 Nov 25;10(12):3041. doi: 10.3390/biomedicines10123041.
10
Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis.非酒精性脂肪性肝炎患者致癌风险评估的 DNA 甲基化定量。
Clin Epigenetics. 2022 Dec 5;14(1):168. doi: 10.1186/s13148-022-01379-4.